Literature DB >> 28197637

Inhibition of FASN suppresses migration, invasion and growth in hepatoma carcinoma cells by deregulating the HIF-1α/IGFBP1 pathway.

Jiaojiao Gong1, Shasha Shen1, Yixuan Yang2, Si Qin1, Lifan Huang1, Hongmin Zhang1, Ling Chen1, Yaqin Chen1, Shiying Li1, Sha She1, Min Yang1, Hong Ren1, Huaidong Hu3.   

Abstract

Hepatocellular carcinoma is the second most common cause of cancer-related deaths worldwide. Due to a high propensity to metastasize, active angiogenesis and rapid proliferation, recurrence and poor prognosis are major obstacles for treatment and cure of this disease. However, the detailed mechanisms of how fatty acid synthase (FASN) promotes migration, invasion and healing in tumor cells remain unclear. In the present study, the previous results that FASN was expressed higher in cancer samples than in non-cancerous samples, and influenced migration, invasion of hepatoma carcinoma cells, were verified by immunohistochemistry, tissue microarrays, Transwell assay and wound healing assay. The secretory proteins of hepatocellular carcinoma cells with or without FASN knockdown were analyzed using the isobaric tags for relative and absolute quantitation (iTRAQ) method to identify differentially expressed proteins (DEPs). The DEPs were verified by RT-PCR and western blot analysis, and were consistent with the iTRAQ results. Inhibition of FASN can decrease the levels of IGFBP1, and the expression, activity, and ubiquitination of HIF-1α. Inhibition of FASN can suppress migration, invasion and healing of hepatoma carcinoma cells by decreasing HIF-1α, and IGFBP1.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28197637     DOI: 10.3892/ijo.2017.3867

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

1.  Identification of the fatty acid synthase interaction network via iTRAQ-based proteomics indicates the potential molecular mechanisms of liver cancer metastasis.

Authors:  Juan Huang; Yao Tang; Xiaoqin Zou; Yi Lu; Sha She; Wenyue Zhang; Hong Ren; Yixuan Yang; Huaidong Hu
Journal:  Cancer Cell Int       Date:  2020-07-21       Impact factor: 5.722

2.  Downregulation of PDK4 Increases Lipogenesis and Associates with Poor Prognosis in Hepatocellular Carcinoma.

Authors:  Chen Yang; Siying Wang; Haoyu Ruan; Botai Li; Zhuoan Cheng; Jia He; Qiaozhu Zuo; Chengtao Yu; Hui Wang; Yuanyuan Lv; Dishui Gu; Guangzhi Jin; Ming Yao; Wenxin Qin; Haojie Jin
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

3.  Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss.

Authors:  Débora C Bastos; Caroline F Ribeiro; Thomas Ahearn; Jéssica Nascimento; Hubert Pakula; John Clohessy; Lorelei Mucci; Thomas Roberts; Silvio M Zanata; Giorgia Zadra; Massimo Loda
Journal:  J Pathol       Date:  2020-12-11       Impact factor: 7.996

Review 4.  Regulatory mechanism of HIF-1α and its role in liver diseases: a narrative review.

Authors:  Qingfei Chu; Xinyu Gu; Qiuxian Zheng; Haihong Zhu
Journal:  Ann Transl Med       Date:  2022-01

5.  [Effect of fatty acid synthase gene silencing on lipid metabolism and biological behaviors of human hepatoblastoma HepG2 cells].

Authors:  H Huang; Y Wei; J Wang; F Ran; Q Chen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-05-20

6.  Dysregulated metabolic enzymes and metabolic reprogramming in cancer cells.

Authors:  Annapoorna Sreedhar; Yunfeng Zhao
Journal:  Biomed Rep       Date:  2017-11-21

7.  Inactivation of Stat3 and crosstalk of miRNA155-5p and FOXO3a contribute to the induction of IGFBP1 expression by beta-elemene in human lung cancer.

Authors:  Fang Zheng; Qing Tang; Xiao-Hua Zheng; JingJing Wu; HaiDing Huang; Haibo Zhang; Swei Sunny Hann
Journal:  Exp Mol Med       Date:  2018-09-12       Impact factor: 8.718

8.  Combining bioinformatics techniques to explore the molecular mechanisms involved in pancreatic cancer metastasis and prognosis.

Authors:  Jia-Sheng Xu; Kai-Li Liao; Xinlu Wang; Jiarui He; Xiao-Zhong Wang
Journal:  J Cell Mol Med       Date:  2020-11-09       Impact factor: 5.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.